In Vivo Determinants of Hepatitis C Virus Adaptation and Escape From Neutralizing Antibody AR5A
We show that L665S is an AR5A escape mutation in vivo, supporting the use of cost-effective vaccine escape studies in vitro. We also identify novel in vivo adaptive mutations and characterize their mechanism of action, thus facilitating interpretation of future HCV in vivo studies.
Authors
- Laura Collignon (ORCID: https://orcid.org/0000-0002-5805-4859)
- Jannick Prentoe (ORCID: https://orcid.org/0000-0003-2203-9478)
- Rodrigo Velázquez‐Moctezuma (ORCID: https://orcid.org/0000-0001-9865-152X)
- Mansun Law (ORCID: https://orcid.org/0000-0002-8934-9756)
- Kenn Holmbeck (ORCID: https://orcid.org/0000-0002-4472-3257)
- Jens Bukh (ORCID: https://orcid.org/0000-0002-7815-4806)
- Philip Meuleman (ORCID: https://orcid.org/0000-0001-6821-234X)
- Erick Giang
- Rani Burm (ORCID: https://orcid.org/0000-0002-7947-6161)
- Lieven Verhoye (ORCID: https://orcid.org/0000-0001-8216-5578)
Institutions
- Scripps Research Institute (US)
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Ghent University (BE)
Publication Details
- Journal
- Cellular and Molecular Gastroenterology and Hepatology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jcmgh.2025.101684
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Gentofte Hospital
- Fonds Wetenschappelijk Onderzoek
- Lundbeckfonden
- Novo Nordisk
- Universiteit Gent
- Hvidovre Hospital
- Vlaamse regering
- H. Lundbeck A/S
- National Institutes of Health
- Bijzonder Onderzoeksfonds UGent